Atezolizumab and Bevacizumab for Mucosal Melanoma
Author Information
Author(s): Jie Dai, Tianxiao Xu, Lifeng Li, Meiyu Fang, Jing Lin, Jun Cao, Xue Bai, Caili Li, Xiaoting Wei, Junjie Gu, Jun Guo, Yu Chen, Lili Mao, Lu Si
Primary Institution: Peking University Cancer Hospital and Institute
Hypothesis
Can atezolizumab combined with bevacizumab improve survival outcomes in patients with unresectable or metastatic mucosal melanoma?
Conclusion
The combination of atezolizumab and bevacizumab shows sustained efficacy in patients with advanced mucosal melanoma, particularly in those with upper site tumors and NRAS mutations.
Supporting Evidence
- The median overall survival was 23.7 months with a 3-year OS rate of 28.7%.
- Patients with upper site melanoma had longer progression-free survival.
- NRAS mutations were associated with enhanced angiogenesis and better treatment response.
- Inflammatory cell infiltration and angiogenic status may serve as prognostic indicators.
Takeaway
This study found that a combination of two cancer drugs helps some patients with a rare type of skin cancer live longer and feel better.
Methodology
Patients received atezolizumab and bevacizumab every 3 weeks, with genomic and transcriptomic analyses performed on tumor samples.
Potential Biases
The study may have biases related to the selection of patients and the multi-omics analysis.
Limitations
The study had a limited sample size and potential biases in patient selection.
Participant Demographics
Patients with unresectable or metastatic mucosal melanoma, with a mix of upper and lower site tumors.
Statistical Information
P-Value
p=0.003
Confidence Interval
95% CI, 15.1–34
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website